Search results
Author(s):
Didier Carrie
Added:
3 years ago
According to the International Diabetes Federation, 382 million people had diabetes in 2013, with diabetes mellitus (DM) accounting for around 90 % of all diabetes cases. By 2025 the number will rise to 592 million.1 The association between DM and cardiovascular disease is well established2 and percutaneous coronary intervention (PCI) is associated with worse clinical and angiographic outcomes…
View more
Author(s):
Ehrin J Armstrong
,
Stephen W Waldo
Added:
3 years ago
Patients with diabetes mellitus (DM) have an increased prevalence of coronary artery disease (CAD) and are more likely to require coronary revascularisation than patients without DM.1 Similar to the general population, CAD remains the most frequent cause of death among patients with DM.2 As the prevalence of DM continues to rise worldwide, the appropriate management and method of…
View more
Author(s):
Robert A Byrne
,
Shmuel Banai
,
Roisin Colleran
,
et al
Added:
3 years ago
Newer generation polymeric metallic drug-eluting stents (DES) have shown improved efficacy and safety compared with bare-metal stents and first-generation DES, improving patient outcomes after percutaneous coronary intervention (PCI) and facilitating the treatment of more complex coronary disease.1 However, clinical outcomes in certain lesion and patient subsets remain suboptimal. Procedural and…
View more
Author(s):
Aleardo Maresta
,
Marco Balducelli
,
Elisabetta Varani
Added:
3 years ago
Cardiovascular disease is a major consequence of diabetes and is associated with peculiar features in this subgroup of patients, representing roughly 25% of the total population treated with percutaneous coronary interventions (PCIs). A consistent proportion of these patients have asymptomatic myocardial ischaemia, which is a more extensive and diffuse atherosclerotic disease with more prevalent…
View more
Author(s):
Adrian P Banning
,
Kristin L Hood
,
Aloke V Finn
,
et al
Added:
3 years ago
Patients with diabetes have abnormalities in the growth and function of arterial smooth-muscle and endothelial cells and consequently have a particularly aggressive and diffuse pattern of atherosclerosis, leading to increased cardiovascular complications and mortality compared with the non-diabetic population.1–4 However, the molecular signalling underlying the accelerated atherosclerosis in…
View more
Author(s):
Bertram Pitt
,
Harriette Van Spall
Added:
2 years ago
Late-breaker host, Dr Harriette Van Spall (McMaster University, CA)is joined by Principal Investigator, Dr Bertram Pitt (University of Michigan, US) for an insightful discussion on the FIGARO-DKD Trial presented at ESC Congress 2021.
The aim of study was to asses whether finerenone (Bayer), nonsteroidal mineralocorticoid receptor antagonist (MRA), in addition to standard daily therapy, is…
View more
Author(s):
Donald E Cutlip
Added:
3 years ago
Coronary artery disease is a major cause of morbidity and mortality among patients with diabetes.1 The presence of diabetes is associated with at least a doubling of the risk for subsequent cardiovascular disease and cardiovascular death,2–4 and the diagnosis of coronary artery disease is more difficult in patients with diabetes owing to frequent atypical symptoms or silent ischaemia. Furthermore…
View more
Author(s):
Katrina Mountfort
Added:
3 years ago
Proceedings of Two Satellite Symposia Held at EuroPCR in May 2015 in Paris
The use of second-generation polymeric metallic drug-eluting stents (DES) in percutaneous coronary intervention (PCI) is now routine practice and has demonstrated excellent safety and efficacy compared with first-generation DES. These stents have enhanced PCI procedures, enabling the treatment of more complex lesions and…
View more
Author(s):
Erin A Bohula
Added:
5 years ago
Dr Erin Bohula (Brigham and Women's Hospital, Boston, US) discusses CAMELLIA-TIMI 61 - a study to evaluate the effect of long-term treatment with BELVIQ (Lorcaserin HCl) on the incidence of MACE and conversion to type 2 diabetes mellitus in obese and overweight subjects with CVD or multiple CV risk factors.
Filmed on-site at ESC 2018.
View more
Author(s):
Rafael Romaguera
Added:
2 years ago
In this short interview, Dr Rafael Romaguera (University of Barcelona, SP) discusses the findings from the SUGAR trial.This randomized head-to-head trial aimed to compare Cre8 EVO stents to a contemporary drug-eluting stent (DES) in patients with diabetes (DM) and coronary artery disease. The trial, first presented at TCT 2021, demonstrated that Cre8 EVO stents were non-inferior to Resolute Onyx…
View more